Further emerging evidences are highlighting the pathological functions of abnormally expressed CREB3L1 in the occurrence, progress, and prediction of patients with glioma, breast cancer, and thyroid cancer. This evidence concerns the gene CREB3L1 and thyroid gland carcinoma.